Basic Information
ID DDInter2009
Drug Type small molecule
Molecular Formula C15H19N3O2
Molecular Weight 273.336
CAS Number 1642288-47-8
Description Mavacamten is a myosin inhibitor indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM). It received initial US FDA approval in 2022, and it is one of the first myosin inhibitors to be used in humans.[A248440] Mavacamten was also approved by Health Canada in October 2022.[L44106]
ATC Classification -
IUPAC Name 6-{[(1S)-1-phenylethyl]amino}-3-(propan-2-yl)-1,2,3,4-tetrahydropyrimidine-2,4-dione
InChI RLCLASQCAPXVLM-NSHDSACASA-N
Canonical SMILES CC(C)N1C(=O)NC(N[C@@H](C)C2=CC=CC=C2)=CC1=O
Useful Links DrugBank ChemSpider PharmGKB Wikipedia ChEMBL
Interactions with Mavacamten
Filter:
Severity level ID Name Mechanism Detail
Interactions with diseases
Filter:
Severity level Disease name Text References
Interactions with foods
Filter:
Severity level Food name Description Management Mechanism References
Interactions with compound preparation
Multi-DRUG trade Multi-DRUG Drug type Warning Note